Open company graph database — free web & API
Login

Regenerative Medicine Innovation Forum

一般社団法人再生医療イノベーションフォーラム
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
18
§01

Basic information

BASIC
Head office
2-3-11 Nihonbashi Motomachi, Chuo-ku, TokyoSourcesSources
Chief executive
Kenichiro HatakeSourcesSources
Capital
Employees (non-consolidated)
Employees (consolidated)
Start date
2011-06-17
End date
§02

Websites

1 DOMAINS
§03

Business

3
Building a global networkSourcesInternational information disseminationSourcesEnhancing overall industry valueSources
§04

Related companies

18 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Celsyde Corporation
Group
Takara Bio Inc.
Group
Fuji Film Corporation
Group
Medinet Corporation
Group
Sumitomo Pharma Co., Ltd.
Group
DAIICHI SANKYO COMPANY, LIMITED
Group
Astellas Pharma Inc.
Group
JCR Pharma Corporation
Group
Nipro Corporation
Group
Bristol-Myers Squibb Company
Group
Mitsui Fudosan Co., Ltd.
Group
Hitachi Ltd.
Group
Dai Nippon Printing Co., Ltd.
Group
Novartis Pharma Co., Ltd.
Group
Teijin Inc.
Group
Graphcore Limited
Group
Kyowa Kirin Co., Ltd.
Group
Japan Tissue Engineering Co., Ltd.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

58 EVENTS

Established the Regenerative Medicine Innovation Forum with 14 companiesSources

Held the first general meeting and started committee activitiesSources

Hosted a seminar organized by FIRM at BioJapan 2011 and exhibited at the booth (participated annually thereafter)Sources

Co-hosted Panel Discussion 4 at the 11th Annual Meeting of the Japanese Society for Regenerative Medicine: "Promoting Regenerative Medicine Originating in Japan" (co-hosted annually thereafter)Sources

Contracted by the Ministry of Economy, Trade and Industry and Mitsubishi Research Institute to develop a global certification infrastructureSources

Submitted a request for the promotion of regenerative and cellular medicine to the Chief Cabinet Secretary, Minister of Health, Labour and Welfare, and Chairman of the Regulatory Reform ConferenceSources

Contracted by the Ministry of Economy, Trade and Industry and Mitsubishi Research Institute for international executive dispatch servicesSources

Contracted by the Ministry of Economy, Trade and Industry and Mitsubishi Research Institute for international standardization of regenerative medicine technology, equipment, and transportSources

Supported the World Alliance Forum in San Francisco in collaboration with other organizationsSources

Contracted by Kanagawa Prefecture to survey overseas company needs and clinical trial trends related to regenerative and cellular medicineSources

Sponsored the Regenerative Medicine Industrialization Exhibition hosted by Lead Exhibition Japan and organized four special lecturesSources

Established the Kansai liaison officeSources

Signed a comprehensive cooperation MOU with the U.S. Alliance for Regenerative Medicine (ARM) (subsequently signed MOUs with Sweden, Canada, Australia, the UK, etc.)Sources

Established the Regenerative Medicine Industrialization Demonstration Task Force (RMIT) to advance industrial demonstration studiesSources

Contracted by the Ministry of Economy, Trade and Industry and Mitsubishi Research Institute for an international standardization feasibility study on quality management in the biobank fieldSources

Moved the secretariat from 2-26-9 Hatchobori, Chuo-ku, Tokyo to 2-3-11 Nihonbashi Motomachi, Chuo-ku, TokyoSources

Contracted by the Ministry of Economy, Trade and Industry for the strategic coordinator project (Regenerative Medicine Industrialization Demonstration Project)Sources

Completed and published the "FIRM Guide on Transport Considerations for Cell Processing Products Used in Regenerative Medicine"Sources

Conducted a survey of overseas contract manufacturing organizations (CMOs) for cell therapeuticsSources

Signed a memorandum of understanding to collaborate on promoting regenerative medicine between the Regenerative Medicine Innovation Forum and the Centre for Commercialization of Regenerative Medicine (Canada)Sources

Held the first Regenerative Medicine Crossroad in TokyoSources

Published the FIRM standard "FIRM Guide for Automated Cell Culture Processing Devices for Regenerative Medicine (Guide for Development)"Sources

Published the FIRM case study collection on "FIRM for the Safety Assurance Act for Regenerative Medicine, Article 42: Standards for Structural Facilities"Sources

Signed a memorandum of understanding to collaborate on promoting regenerative medicine between the Regenerative Medicine Innovation Forum and the Council for Advanced Regenerative Medicine (South Korea)Sources

Introduced the current status of Japanese regenerative medicine at the Cell & Gene Meeting on the MESA 2016 workshop (participating annually thereafter)Sources

Co-hosted "Regenerative Medicine Japan" with JBA at BioJapan 2016, presented at the booth, and held four seminar sessionsSources

Co-hosted the Regenerative Medicine Industry-Academia-Government Collaboration SymposiumSources

Held the first Regenerative Medicine Venture Creation Support SeminarSources

ISO approved the international standard proposal for the design process of transport specifications for cells and related materials as a new business itemSources

Published the FIRM guide on considerations when selecting plastic instruments used in the processing and storage of cells for regenerative medicineSources

Received a contract from the Ministry of Economy, Trade and Industry and Mitsubishi Research Institute for an international standardization project on cell characteristic evaluation and application to product manufacturingSources

Published the "Medium Supplier FIRM Guide for Culture Media Products"Sources

Signed a memorandum of understanding to collaborate on promoting regenerative medicine with the UK Cell and Gene Therapy Catapult (CGT Catapult)Sources

Signed a comprehensive collaboration memorandum with the International Society for Cellular Therapy (ISCT)Sources

Signed a memorandum of understanding to collaborate on promoting regenerative medicine with the Australian biotechnology industry association (AusBiotech)Sources

Published "FIRM Case Study Collection on Test and Inspection Methods/Equipment (Volume 1) – Quality Management of Cells and Related Materials Provided Under the Regenerative Medicine Safety Assurance Act"Sources

Signed a memorandum of understanding to collaborate on promoting regenerative medicine with the Israel Stem Cell Society (ISCS)Sources

Publication of "FIRM Guide on Transport Considerations for Cell Processing Products Used in Regenerative Medicine, 2nd Edition"Sources

Hosted the First Asia Regenerative Medicine Organization Collaboration Conference (APACRM) (held annually thereafter)Sources

Signed a memorandum of understanding for collaboration between the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and regenerative medicine to promote the fieldSources

Presented Japan's contribution to standardization in regenerative medicine at a session on cell therapy and gene therapy standardization by the International Society for Cellular Therapy (ISCT)Sources

FIRM Standardization Committee Chair appointed as a director of the U.S. Standards Coordinating Body (SCB)Sources

First Entrepreneurial Workshop (providing know-how and support to researchers considering starting venture companies, held multiple times annually thereafter)Sources

Issued the ISO standard for raw material specifications (ISO/TS 20399 series)Sources

Publication of "FIRM Guide on Considerations When Selecting Plastic Instruments for Cell Processing and Storage in Regenerative Medicine, 2nd Edition"Sources

Established the FIRM education system "Clinical Cell Culture Technician Training Program" in collaboration with the Japan Society for Regenerative MedicineSources

ISO issued an international standard (technical specification) on ancillary materials for manufacturing regenerative medicine products proposed by JapanSources

Hosted the symposium "Integrating Industry, Government, Academia, and Civil Society for International Standardization – Impact on Regenerative Medicine" at the 18th Annual Meeting of the Japan Society for Regenerative MedicineSources

Commenced full operation of the FIRM education system "Clinical Cell Culture Technician Training Program"Sources

Hosted the 7th meeting of ISO/TC 276 and the joint working group at Nihonbashi Life Science HubSources

Released the first FIRM monograph "Guide for Licensing and Renewal Applications for Regenerative Medicine Products and Specific Cell Processing Products under the Pharmaceutical and Medical Device Act and the Regenerative Medicine Act: For Domestic and International Companies and Medical Institutions Involved in Regenerative Medicine" by Seibundo ShinchoshaSources

Initiated new organizational structureSources

Established the "Regenerative Medicine Products Committee"Sources

Published the "Checklist for Regenerative Medicine Product Development to Approval" exclusively for membersSources

Renovated the FIRM website to strengthen information dissemination to internal and external audiencesSources

Established the "Transparency Guidelines" and fully implemented them from fiscal year 2023Sources

Launched the FIRM 10th Anniversary project with a collaboration initiative featuring YouTubersSources

Establishment of the "Committee on Specific Cell Processing Products and the Like"Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information6010005017149
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
一般社団法人再生医療イノベーションフォーラム
Trade name (kana)
サイセイイリョウイノベーションフォーラム
Name in English
Corporation type
399
Address
〒103-0023 東京都中央区日本橋本町2丁目3番11号
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-06-22
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2036126
METI gBizINFO6010005017149
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6010005017149
Trade name
一般社団法人再生医療イノベーションフォーラム
Trade name (kana)
サイセイイリョウイノベーションフォーラム
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区日本橋本町2丁目3番11号
Postal code
1030023
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
日本橋本町2丁目3番11号
Organisation type
399
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-06-22
Key information
6010005017149
§09

Sources & updates

SOURCES
↑